| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Jan, 2026 | Jan, 2026 |
| Sales | 0 | 2,000 | 0 | 0 | 0 |
| Sales Growth | -100.00% | unch | unch | unch | unch |
| Net Income | -45,570 | -27,880 | -30,500 | 0 | 0 |
| Net Income Growth | -63.45% | +8.59% | unch | unch | unch |
Sagimet Biosciences Inc Series A (SGMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel therapeutics targeting dysfunctional metabolic pathways. Sagimet Biosciences Inc. is based in SAN MATEO, Calif.
Fiscal Year End Date: 12/31